- Home
- FFIV vs RPRX Comparison
FFIV vs RPRX Comparison
Compare FFIV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIV
- RPRX
- Stock Information
- Founded
- FFIV 1996
- RPRX 1996
- Country
- FFIV United States
- RPRX United States
- Employees
- FFIV N/A
- RPRX N/A
- Industry
- FFIV Computer Communications Equipment
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FFIV Telecommunications
- RPRX Health Care
- Exchange
- FFIV Nasdaq
- RPRX Nasdaq
- Market Cap
- FFIV 16.7B
- RPRX 16.2B
- IPO Year
- FFIV 1999
- RPRX 2020
- Fundamental
- Price
- FFIV $248.49
- RPRX $37.26
- Analyst Decision
- FFIV Hold
- RPRX Strong Buy
- Analyst Count
- FFIV 11
- RPRX 3
- Target Price
- FFIV $297.22
- RPRX $46.00
- AVG Volume (30 Days)
- FFIV 1.2M
- RPRX 2.2M
- Earning Date
- FFIV 10-27-2025
- RPRX 11-05-2025
- Dividend Yield
- FFIV N/A
- RPRX 2.36%
- EPS Growth
- FFIV 23.56
- RPRX 54.86
- EPS
- FFIV 11.80
- RPRX 2.32
- Revenue
- FFIV $3,088,072,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- FFIV $6.12
- RPRX $35.10
- Revenue Next Year
- FFIV $4.49
- RPRX $2.13
- P/E Ratio
- FFIV $21.11
- RPRX $16.05
- Revenue Growth
- FFIV 9.66
- RPRX 3.02
- 52 Week Low
- FFIV $227.05
- RPRX $24.05
- 52 Week High
- FFIV $346.00
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- FFIV 20.37
- RPRX 56.70
- Support Level
- FFIV $294.00
- RPRX $35.92
- Resistance Level
- FFIV $305.35
- RPRX $37.40
- Average True Range (ATR)
- FFIV 11.09
- RPRX 0.73
- MACD
- FFIV -6.54
- RPRX 0.05
- Stochastic Oscillator
- FFIV 0.96
- RPRX 76.10
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.